Roth Capital Reiterates Buy On BioCryst Pharma Following News That It Intends To Join Race To Treat Ebola
In a research report issued Friday, Roth Capital analyst Ed Arce reiterated a Buy rating on BioCryst Pharmaceuticals (NASDAQ: BCRX) with a price target of $20, following the news that BCRX has joined the competition to find an effective treatment for Ebola.
Arce wrote, “Given BioCryst’s strong preclinical data for BCX4430 specifically in Marburg virus, we see a solid rationale for quickly advancing development of the drug for Ebola virus, which is in the same Filoviridae family of RNA viruses. Both diseases are Category A Priority Pathogens of NIAID and Category A Bioterrorism Agents of the Centers for Disease Control and Prevention (CDC).” The analyst added, “We recognize this “Ebola play” for what it is: a wild card opportunity that potentially represents meaningful upside to our estimates and non-dilutive cash for BioCryst’s HAE program.”
According to TipRanks.com, which measures analysts’ and bloggers’ success rate based on how their calls perform, analyst Ed Arce has a total average return of 26.8% and a 65.4% success rate. Arce has a 107.1% average return when recommending BCRX, and is ranked #209 out of 3248 analysts.